Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 27, 2023--

Related Keywords

United States ,Massachusetts ,David Burke ,Ptoddc Brady ,Garyn Gross ,Dallas Allergy Asthma Center ,Aldeyra Therapeutics Inc ,Exchange Commission ,Nasdaq ,Drug Administration New Application ,Securities Exchange ,Clinical Professor ,Internal Medicine ,Southwestern Medical School ,Dallas Allergy ,Investor Relations ,Aldeyra Therapeutics ,Drug Administration New Application Review ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Financial Condition ,Annual Report ,Quarterly Report ,Business Wire ,Region ,